Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature

<div>ACTH, morning cortisol, and UFC trends during the follow-up after SSA treatment and surgery. Short-term (13 days) octreotide therapy prompted marked reductions in ACTH levels (from 131 to 63 pg/mL) and cortisol levels (from 57.47 to 7.16 <i>μ</i>g/dL), and UFC levels decreased to the normal range (55 <i>μ</i>g per day). Surgery and long-term octreotide LAR therapy maintained the hormones normally, with ACTH fluctuating from 23.0 to 53.4 ng/L and UFC fluctuating from 6.96 to 48.84 <i>μ</i>g/24 h.</div>

International Journal of Endocrinology

fig3

Figure 3

Figure 3: Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature 